Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ( " Theravance Biopharma " or the " Company " ) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials